Cargando…

NF‐κB signaling in inflammation and cancer

Since nuclear factor of κ‐light chain of enhancer‐activated B cells (NF‐κB) was discovered in 1986, extraordinary efforts have been made to understand the function and regulating mechanism of NF‐κB for 35 years, which lead to significant progress. Meanwhile, the molecular mechanisms regulating NF‐κB...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tao, Ma, Chao, Zhang, Zhiqiang, Zhang, Huiyuan, Hu, Hongbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706767/
https://www.ncbi.nlm.nih.gov/pubmed/34977871
http://dx.doi.org/10.1002/mco2.104
_version_ 1784622272348160000
author Zhang, Tao
Ma, Chao
Zhang, Zhiqiang
Zhang, Huiyuan
Hu, Hongbo
author_facet Zhang, Tao
Ma, Chao
Zhang, Zhiqiang
Zhang, Huiyuan
Hu, Hongbo
author_sort Zhang, Tao
collection PubMed
description Since nuclear factor of κ‐light chain of enhancer‐activated B cells (NF‐κB) was discovered in 1986, extraordinary efforts have been made to understand the function and regulating mechanism of NF‐κB for 35 years, which lead to significant progress. Meanwhile, the molecular mechanisms regulating NF‐κB activation have also been illuminated, the cascades of signaling events leading to NF‐κB activity and key components of the NF‐κB pathway are also identified. It has been suggested NF‐κB plays an important role in human diseases, especially inflammation‐related diseases. These studies make the NF‐κB an attractive target for disease treatment. This review aims to summarize the knowledge of the family members of NF‐κB, as well as the basic mechanisms of NF‐κB signaling pathway activation. We will also review the effects of dysregulated NF‐κB on inflammation, tumorigenesis, and tumor microenvironment. The progression of the translational study and drug development targeting NF‐κB for inflammatory diseases and cancer treatment and the potential obstacles will be discussed. Further investigations on the precise functions of NF‐κB in the physiological and pathological settings and underlying mechanisms are in the urgent need to develop drugs targeting NF‐κB for inflammatory diseases and cancer treatment, with minimal side effects.
format Online
Article
Text
id pubmed-8706767
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-87067672021-12-30 NF‐κB signaling in inflammation and cancer Zhang, Tao Ma, Chao Zhang, Zhiqiang Zhang, Huiyuan Hu, Hongbo MedComm (2020) Reviews Since nuclear factor of κ‐light chain of enhancer‐activated B cells (NF‐κB) was discovered in 1986, extraordinary efforts have been made to understand the function and regulating mechanism of NF‐κB for 35 years, which lead to significant progress. Meanwhile, the molecular mechanisms regulating NF‐κB activation have also been illuminated, the cascades of signaling events leading to NF‐κB activity and key components of the NF‐κB pathway are also identified. It has been suggested NF‐κB plays an important role in human diseases, especially inflammation‐related diseases. These studies make the NF‐κB an attractive target for disease treatment. This review aims to summarize the knowledge of the family members of NF‐κB, as well as the basic mechanisms of NF‐κB signaling pathway activation. We will also review the effects of dysregulated NF‐κB on inflammation, tumorigenesis, and tumor microenvironment. The progression of the translational study and drug development targeting NF‐κB for inflammatory diseases and cancer treatment and the potential obstacles will be discussed. Further investigations on the precise functions of NF‐κB in the physiological and pathological settings and underlying mechanisms are in the urgent need to develop drugs targeting NF‐κB for inflammatory diseases and cancer treatment, with minimal side effects. John Wiley and Sons Inc. 2021-12-16 /pmc/articles/PMC8706767/ /pubmed/34977871 http://dx.doi.org/10.1002/mco2.104 Text en © 2021 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Zhang, Tao
Ma, Chao
Zhang, Zhiqiang
Zhang, Huiyuan
Hu, Hongbo
NF‐κB signaling in inflammation and cancer
title NF‐κB signaling in inflammation and cancer
title_full NF‐κB signaling in inflammation and cancer
title_fullStr NF‐κB signaling in inflammation and cancer
title_full_unstemmed NF‐κB signaling in inflammation and cancer
title_short NF‐κB signaling in inflammation and cancer
title_sort nf‐κb signaling in inflammation and cancer
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706767/
https://www.ncbi.nlm.nih.gov/pubmed/34977871
http://dx.doi.org/10.1002/mco2.104
work_keys_str_mv AT zhangtao nfkbsignalingininflammationandcancer
AT machao nfkbsignalingininflammationandcancer
AT zhangzhiqiang nfkbsignalingininflammationandcancer
AT zhanghuiyuan nfkbsignalingininflammationandcancer
AT huhongbo nfkbsignalingininflammationandcancer